Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Modifying Adhesion Protein Interactions Prevents Metastasis in Mouse Models

By BiotechDaily International staff writers
Posted on 04 Feb 2014
Image: Normal breast tissue and invasive ductal carcinoma stained brown with antibodies to activated FAK. Blood vessels are indicated by BV (Photo courtesy of Dr. David Schlaepfer, University of California, San Diego).
Image: Normal breast tissue and invasive ductal carcinoma stained brown with antibodies to activated FAK. Blood vessels are indicated by BV (Photo courtesy of Dr. David Schlaepfer, University of California, San Diego).
Cancer investigators have identified a protein critically linked to the process of metastasis by which cancer cells break away from the primary tumor and spread to other parts of the body.

Investigators at the University of California, San Diego (USA) worked with several different mouse cancer models, which they manipulated by pharmacological or genetic means. Of particular interest was the role of the protein focal adhesion kinase (FAK). FAK is a 125-kD protein that is known to participate in focal adhesion dynamics between cells with a role in motility and cell survival. FAK is a highly conserved, nonreceptor tyrosine kinase originally identified as a substrate for the oncogene protein, tyrosine kinase v-src. This cytosolic kinase has been implicated in diverse cellular roles including cell locomotion, mitogen response, and cell survival. FAK is typically located at structures known as focal adhesions, which are multiprotein structures that link the extracellular matrix (ECM) to the cytoplasmic cytoskeleton.

Results published in the January 20, 2014, online edition of the Journal of Cell Biology revealed that FAK was active in both tumors and surrounding endothelial cells and that selective FAK inhibition within endothelial cells prevented spontaneous tumor metastasis without alterations in tumor size. In a mouse melanoma model, FAK inhibition in endothelial cells prevented skin tumors from metastasizing to the lungs without affecting primary tumor growth.

The investigators found that at the molecular level tyrosine 658 of the protein vascular endothelial cadherin was a target of FAK in tumor-associated endothelial cells. Cadherins are members of a family of calcium-dependent cell adhesion proteins that preferentially interact in a homophilic manner in cell-cell interactions. They are type I membrane proteins that contribute to the sorting of heterogeneous cell types. Typically, cadherins have five similar extracellular domains, the outermost three of which have Ca2+-binding sites, and an intracellular C-terminal domain that interacts with the actin cytoskeleton.

Cadherin normally helps to maintain an endothelial cell barrier that surrounds the tumor and prevents metastasis. However, when modified by FAK, the cadherin complexes became degraded and blood vessels became porous. Inactivating FAK within endothelial cells prevented this permeability and blocked the ability of tumor cells to pass through endothelial cell barriers.

“Our studies show that pharmacological or genetic inhibition of the endothelial protein focal adhesion kinase, or FAK, prevents tumor spread by enhancing the vessel barrier function,” said senior author Dr. David D. Schlaepfer, professor of reproductive medicine at the University of California, San Diego. “Metastasis is responsible for 90% of cancer-related deaths. This fact alone underscores the need for a better mechanistic understanding of the metastatic process.”

Related Links:

University of California, San Diego



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.